Human Insulin Market: Jsbmarketresearch

Global Human Insulin Market 2015-2019

Released On 30th September 2015

About diabetes

Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as Human insulin and insulin analogs are available as insulin replacement therapy.

Technavios analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

Covered in this Report

The report includes the present scenario and the growth prospects of the Global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

Technavios report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.

Key Vendors

Eli Lilly

Novo Nordisk

Sanofi

Other Prominent Vendors

Biocon

Biodel

Biogenomics

Boehringer Ingelheim

Bristol-Myers Squibb

Diamyd Medical

Diasome Pharmaceuticals

DiaVacs

Pfizer

Generex Biotechnology

Lexicon Pharmaceuticals

Macrogenics

Merck

Oramed Pharmaceuticals

Osiris Therapeutics...